BIOMAT Database Logo BIOMAT Database Logo

Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy. 2015

Frank Matthes, and Claes Andersson, and Axel Stein, and Carl Eistrup, and Jens Fogh, and Volkmar Gieselmann, and David A Wenger, and Ulrich Matzner
Rheinische Friedrich-Wilhelms University, Institute of Biochemistry and Molecular Biology, Nussallee 11, D-53115 Bonn, Germany.

An inherited deficiency of β-galactosylceramidase (GALC) causes the lysosomal storage disease globoid cell leukodystrophy (GLD). The disease is characterized by the accumulation of the cytotoxic metabolite psychosine (galactosylsphingosine), causing rapid degeneration of myelinating cells. Most patients suffer from the infantile form of GLD with onset of disease between 3 and 6 months after birth and death by 2 years of age. The most widely used animal model of GLD, the twitcher mouse, presents with an even more rapid course of disease and death around 40 days of age. We have generated a novel "humanized" mouse model of GLD by inserting a human GALC cDNA containing an adult-onset patient mutation into the murine GALC gene. Humanized GALC mice exhibit pathological hallmarks of GLD including psychosine accumulation, neuroinflammation, CNS infiltration of macrophages, astrogliosis and demyelination. Residual GALC activities in mouse tissues are low and the mice display a median lifespan of 46 days. Due to the expression of the human transgene, the mice do not develop an immune response against rhGALC, rendering the animal model suitable for therapies based on human enzyme. Intravenously injected rhGALC was able to surmount the blood-brain barrier and was targeted to lysosomes of brain macrophages, astrocytes and neurons. High-dose enzyme replacement therapy started at postnatal day 21 reduced the elevated psychosine levels in the peripheral and central nervous system by 14-16%, but did not ameliorate neuroinflammation, demyelination and lifespan. These results may indicate that treatment must be started earlier before pathology occurs.

UI MeSH Term Description Entries
D007965 Leukodystrophy, Globoid Cell An autosomal recessive metabolic disorder caused by a deficiency of GALACTOSYLCERAMIDASE leading to intralysosomal accumulation of galactolipids such as GALACTOSYLCERAMIDES and PSYCHOSINE. It is characterized by demyelination associated with large multinucleated globoid cells, predominantly involving the white matter of the central nervous system. The loss of MYELIN disrupts normal conduction of nerve impulses. Diffuse Globoid Body Sclerosis,Galactosylceramidase Deficiency Disease,Krabbe Disease,Classic Globoid Cell Leukodystrophy,Early-Onset Globoid Cell Leukodystrophy,GALC Deficiency,Galactocerebrosidase Deficiency,Galactosylceramide Lipidosis,Galactosylceramide beta-Galactosidase Deficiency,Galactosylceramide-beta-Galactosidase Deficiency Disease,Galactosylcerebrosidase Deficiency,Galactosylsphingosine Lipidosis,Globoid Body Sclerosis, Diffuse,Globoid Cell Leukodystrophy,Globoid Cell Leukoencephalopathy,Globoid Leukodystrophy,Infantile Globoid Cell Leukodystrophy,Krabbe Leukodystrophy,Krabbe's Disease,Krabbe's Leukodystrophy,Late-Onset Globoid Cell Leukodystrophy,Leukodystrophy, Globoid Cell, Classic,Leukodystrophy, Globoid Cell, Early-Onset,Leukodystrophy, Globoid Cell, Infantile,Leukodystrophy, Globoid Cell, Late-Onset,Psychosine Lipidosis,Cell Leukodystrophies, Globoid,Cell Leukodystrophy, Globoid,Cell Leukoencephalopathies, Globoid,Cell Leukoencephalopathy, Globoid,Deficiencies, GALC,Deficiencies, Galactocerebrosidase,Deficiencies, Galactosylceramide beta-Galactosidase,Deficiency Disease, Galactosylceramidase,Deficiency Disease, Galactosylceramide-beta-Galactosidase,Deficiency Diseases, Galactosylceramidase,Deficiency Diseases, Galactosylceramide-beta-Galactosidase,Deficiency, GALC,Deficiency, Galactocerebrosidase,Deficiency, Galactosylceramide beta-Galactosidase,Disease, Galactosylceramidase Deficiency,Disease, Galactosylceramide-beta-Galactosidase Deficiency,Diseases, Galactosylceramidase Deficiency,Diseases, Galactosylceramide-beta-Galactosidase Deficiency,Early Onset Globoid Cell Leukodystrophy,GALC Deficiencies,Galactocerebrosidase Deficiencies,Galactosylceramidase Deficiency Diseases,Galactosylceramide beta Galactosidase Deficiency,Galactosylceramide beta Galactosidase Deficiency Disease,Galactosylceramide beta-Galactosidase Deficiencies,Galactosylceramide-beta-Galactosidase Deficiency Diseases,Globoid Cell Leukodystrophies,Globoid Cell Leukoencephalopathies,Globoid Leukodystrophies,Krabbes Disease,Krabbes Leukodystrophy,Late Onset Globoid Cell Leukodystrophy,Leukodystrophies, Globoid,Leukodystrophies, Globoid Cell,Leukodystrophy, Globoid,Leukodystrophy, Krabbe,Leukodystrophy, Krabbe's,Leukoencephalopathies, Globoid Cell,Leukoencephalopathy, Globoid Cell,beta-Galactosidase Deficiencies, Galactosylceramide,beta-Galactosidase Deficiency, Galactosylceramide
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009186 Myelin Sheath The lipid-rich sheath surrounding AXONS in both the CENTRAL NERVOUS SYSTEMS and PERIPHERAL NERVOUS SYSTEM. The myelin sheath is an electrical insulator and allows faster and more energetically efficient conduction of impulses. The sheath is formed by the cell membranes of glial cells (SCHWANN CELLS in the peripheral and OLIGODENDROGLIA in the central nervous system). Deterioration of the sheath in DEMYELINATING DISEASES is a serious clinical problem. Myelin,Myelin Sheaths,Sheath, Myelin,Sheaths, Myelin
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D011609 Psychosine An intermediate in the biosynthesis of cerebrosides. It is formed by reaction of sphingosine with UDP-galactose and then itself reacts with fatty acid-Coenzyme A to form the cerebroside. Galactosylsphingosine,Sphingosine Galactoside,Galactoside, Sphingosine
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002490 Central Nervous System The main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges. Cerebrospinal Axis,Axi, Cerebrospinal,Axis, Cerebrospinal,Central Nervous Systems,Cerebrospinal Axi,Nervous System, Central,Nervous Systems, Central,Systems, Central Nervous

Related Publications

Frank Matthes, and Claes Andersson, and Axel Stein, and Carl Eistrup, and Jens Fogh, and Volkmar Gieselmann, and David A Wenger, and Ulrich Matzner
Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy.
September 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Frank Matthes, and Claes Andersson, and Axel Stein, and Carl Eistrup, and Jens Fogh, and Volkmar Gieselmann, and David A Wenger, and Ulrich Matzner
[Globoid cell leukodystrophy: enzymatic diagnosis in two families, and enzyme replacement therapy (author's transl)].
July 1978, No to shinkei = Brain and nerve,
Frank Matthes, and Claes Andersson, and Axel Stein, and Carl Eistrup, and Jens Fogh, and Volkmar Gieselmann, and David A Wenger, and Ulrich Matzner
Additional deficiency of psychosine galactosidase in globoid cell leukodystrophy: an implication to enzyme replacement therapy.
March 1973, Birth defects original article series,
Frank Matthes, and Claes Andersson, and Axel Stein, and Carl Eistrup, and Jens Fogh, and Volkmar Gieselmann, and David A Wenger, and Ulrich Matzner
Macrophages counteract demyelination in a mouse model of globoid cell leukodystrophy.
March 2011, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Frank Matthes, and Claes Andersson, and Axel Stein, and Carl Eistrup, and Jens Fogh, and Volkmar Gieselmann, and David A Wenger, and Ulrich Matzner
The twitcher mouse. A model of human globoid cell leukodystrophy (krabbe's disease).
June 1983, The American journal of pathology,
Frank Matthes, and Claes Andersson, and Axel Stein, and Carl Eistrup, and Jens Fogh, and Volkmar Gieselmann, and David A Wenger, and Ulrich Matzner
Neural stem cell gene therapy ameliorates pathology and function in a mouse model of globoid cell leukodystrophy.
October 2011, Stem cells (Dayton, Ohio),
Frank Matthes, and Claes Andersson, and Axel Stein, and Carl Eistrup, and Jens Fogh, and Volkmar Gieselmann, and David A Wenger, and Ulrich Matzner
Bone marrow transplantation increases efficacy of central nervous system-directed enzyme replacement therapy in the murine model of globoid cell leukodystrophy.
September 2012, Molecular genetics and metabolism,
Frank Matthes, and Claes Andersson, and Axel Stein, and Carl Eistrup, and Jens Fogh, and Volkmar Gieselmann, and David A Wenger, and Ulrich Matzner
[Globoid cell leukodystrophy].
January 1983, Pathologica,
Frank Matthes, and Claes Andersson, and Axel Stein, and Carl Eistrup, and Jens Fogh, and Volkmar Gieselmann, and David A Wenger, and Ulrich Matzner
[Globoid cell leukodystrophy].
January 1970, Acta neurologica latinoamericana,
Frank Matthes, and Claes Andersson, and Axel Stein, and Carl Eistrup, and Jens Fogh, and Volkmar Gieselmann, and David A Wenger, and Ulrich Matzner
CD8+ T cell depletion prevents neuropathology in a mouse model of globoid cell leukodystrophy.
September 2023, The Journal of experimental medicine,
Copied contents to your clipboard!